Drugs / ChAdOx1 RVF
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04754776 | Jun 2021 → Apr 2022 | Rift valley fever | University of Oxford | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04672824 | May → Dec 2022 | Rift valley fever | University of Oxford | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06799234 | Jul 2025 → Mar 2026 overdue | Rift valley fever | University of Oxford | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAdOx1 RVF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04754776 ↗ |
| Modality | Vaccine | “a non-replicating simian adenovirus-vectored Rift Valley fever (ChAdOx1 RVF) vaccine in humans” PMID 37060917 ↗ Apr 2023 |
| Route | Intramuscular | “The vaccine will be administered intramuscularly.” NCT04672824 ↗ |